Back to top
more

Johnson & Johnson (JNJ)

(Real Time Quote from BATS)

$162.17 USD

162.17
1,948,365

-1.05 (-0.64%)

Updated Sep 24, 2024 01:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Keytruda Drive Merck's (MRK) Q1 Earnings and Sales?

by Zacks Equity Research

Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive first-quarter sales. However, genericization of key drugs and increasing competition are concerns.

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Raises EPS View

by Zacks Equity Research

AbbVie (ABBV) beats first-quarter estimates for both earnings and revenues. Biosimilar competition impacts Humira sales in ex-U.S. markets. Growth in Imbruvica sales offsets Humira decline.

Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales

by Zacks Equity Research

Biogen (BIIB) beats estimates for both earnings and sales in the first quarter fueled mainly by strong performance of its muscle disease drug, Spinraza in international markets.

Here Are the Key Takeaways From J&J's Q1 Earnings Report

by Zacks Equity Research

Let's have a look at some of the highlights of J&J's (JNJ) first-quarter 2019 results.

Stock Market News For Apr 17, 2019

by Zacks Equity Research

Markets closed higher on Tuesday as investors welcomed a spate of healthy first quarter earnings results.

Axsome's AXS-05 Meets Goal in Phase II Study, Shares Up

by Zacks Equity Research

Axsome's (AXSM) mid-stage candidate, AXS-05, achieves the primary endpoint in a phase II study as a smoking cessation treatment. Shares rise.

J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.

Q1 Earnings To Watch For

by Zacks Equity Research

Q1 Earnings To Watch For

Mark Vickery headshot

Q1 Earnings Spigot Opens: JNJ, BAC, UNH & More

by Mark Vickery

This is the first "full week" of Q1 earnings season, though the influx of reports hitting the tape in the next few weeks to come will be even heavier.

Johnson & Johnson (JNJ) is a Top Dividend Stock Right Now: Should You Buy?

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.

J&J (JNJ) Tops Q1 Earnings; Pharma Segment Drives Sales

by Zacks Equity Research

J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019. Hikes 2019 guidance for operational sales and earnings growth. Shares up in pre-market trading.

Johnson & Johnson (JNJ) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 3.45% and 2.01%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

J&J's Erdafitinib Gets FDA Approval for Urothelial Cancer

by Zacks Equity Research

FDA grants approval to J&J's (JNJ) erdafitinib for metastatic urothelial cancer, a type of bladder cancer. This is J&J's second FDA approval for a new drug in less than two months

David Borun headshot

Banks Deliver and the Rally Continues

by David Borun

After an encouraging start to earnings season, stocks continue to rise.

Kinjel Shah headshot

Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal

by Kinjel Shah

Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.

Looking for a Growth Stock? 3 Reasons Why Johnson & Johnson (JNJ) is a Solid Choice

by Zacks Equity Research

Johnson & Johnson (JNJ) could produce exceptional returns because of its solid growth attributes.

Sheraz Mian headshot

Earnings Optimism Following Bank Results

by Sheraz Mian

If we aggregate these positive surprises to the entire S&P 500 index, then it is reasonable to envision a Q1 earnings growth pace that may not be negative, after all.

Novartis to Market Rizmoic Through Sandoz, Spins Off Alcon

by Zacks Equity Research

Novartis' (NVS) Sandoz signs an agreement with Japanese company, Shionogi, to commercialize constipation drug in key European markets.

Sweta Jaiswal, FRM headshot

Biotechnology Market on a Tear: 5 ETFs in Spotlight

by Sweta Jaiswal, FRM

Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.

Sweta Killa headshot

What's in Store for Dow ETF in Q1 Earnings?

by Sweta Killa

Let's delve into the Q1 earnings picture that will likely set up the movement of the Dow Jones ETF in the coming days.

Ra Pharmaceuticals Closes End-of-Phase 2 Interaction with FDA

by Zacks Equity Research

Ra Pharmaceuticals (RARX) closes the End-of-Phase II interactions with the FDA for its phase III study on zilucoplan for the treatment of generalized myasthenia gravis (gMG).

Alkermes Reports Positive Data From Schizophrenia Study

by Zacks Equity Research

Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.

Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

by Zacks Equity Research

Akebia Therapeutics (AKBA) and Vifor Pharma expand licensing agreement related to commercialization of Akeba's pipeline candidate, vadadustat, to include additional dialysis organizations.

J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?

by Zacks Equity Research

J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.

Swarup Gupta headshot

5 Stocks to Prepare for a Global Economic Slowdown

by Swarup Gupta

In such an event, demand for products and services generated by utilities, consumer staples and medical companies remain invariant.